Creating drugs at the speed of AI.

absci®

DRUG CREATION

```python
from absci import de_novo_model
model = de_novo_model.load_latest()
antigen = model.load_pdb("7olz.pdb",
chain="A")
antibodies = model.predict(antigen, N=300000)
```

```python
from absci_library import codon_optimizer
library
= codon_optimizer.reverse_translate(library)
library.to_csv("covid-antibody-designs.csv")
library.to_wet_lab(assay="ACE")
```

```python
from absci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest()
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab(as
say="SPR")
```

2005: 20 approved, 11.2% of drugs entering clinical trials approved 2006: 22 approved, 11.2% 2007: 18 approved, 10.7% 2008: 24 approved, 9.2% 2009: 26 approved, 7.8% 2010: 21 approved, 6.8% 2011: 35 approved, 6.1% 2012: 39 approved, 5.3% 2013: 27 approved, 5.2% 2014: 41 approved, 6.7% 2015: 45 approved, 13.8%
Oxford Academic

Disclaimers

Forward-Looking Statements

Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predicts," "advancing," "aim," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, financial performance and results of operations, including our expectations and guidance regarding cash, cash equivalents and restricted cash, our projected cash usage, needs and runway, future operations, future financial position, future revenue, internal research and technological development activities, advancements toward in silico drug design, research and technology development collaboration efforts, growth plans, projected costs, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to the development of our technology, our ability to secure milestone payments and royalties, and our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Market and Statistical Information

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness.

Trademark usage

This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absci®, **absci**. , SoluPro® and SoluPure® are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and trade names in our business, including the Absci logo mark (**a**), the Absci AI logo mark (**ai**), the Unlimit with us mark (Unlimit With Us™), the unlimit symbol (unlimit), Bionic protein, Bionic Enzyme, Bionic Antibody, Bionic SoluPro, Denovium, Denovium Engine, Drug Creation, Integrated Drug Creation, HiPrBind, HiPrBind Assay, Translating Ideas into Drugs, Translating Ideas into Impact, We Translate Ideas into Drugs, and We Translate Ideas into Impact. All other trademarks, service marks or trade names referred to in this presentation/document/webpage are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation/document/webpage may be referred to with or without the trademark symbols, but references which omit the symbols should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

What if the next transformative drug was not discovered but created with a click of a button?

Chat GPT

Text to image (DALL-E)

Natural Language Translation

Image recognition

HISTORY OF AI

10 YEARS AGO

TODAY

DALL-E generated image of Penelope (Absci's Chief Morale Officer) discovering biologics on a computer.

The old drug discovery paradigm is ripe for disruption

5.5 YEARS FROM DISCOVERY TO IND

<5% SUCCESS RATE FROM DISCOVERY TO LAUNCH

OPTIMIZE FOR AFFINITY

OPTIMIZE FOR DEVELOPABILITY

OPTIMIZE FOR TOXICITY

SUBOPTIMAL CANDIDATE

Long iterative process creating drug candidates with suboptimal attributes

Unlocking the potential of generative AI in biology require scalable biological data

Small molecule   v.   Biologic

Extensive Libraries

Limited Data

Biologics requires living organisms to make every drug variant for testing

Consistency and accurate data is limited

Unlocking the potential of generative AI in biology…

WET LAB   AI

…requires generating scalable biological data

# Absci is solving the problem of scalable biological data enabling true generative AI for biologics drug discovery

Absci's *E.coli* SoluPro™ cell line

Billions of cells, expressing proteins-of-interest

Absci's ACE Assay screens billions of unique drug variant candidates

High-quality data flows into Absci's generative AI engine

● NON-BINDING
● TIGHT BINDING

At Absci, the future is now with our Integrated Drug Creation™ platform

DATA TO TRAIN

Proprietary wet-lab assays capable of generating billions of protein-protein interactions a week for ML training

WET LAB TO VALIDATE

Scalable wet-lab infrastructure capable of validating 2.8 million unique AI-generated designs a week

AI TO CREATE

Generative AI engine to create new antibodies and next-gen biologics

Absci is the Leader in Generative AI Drug Creation for Biologics
# Cycles completed within weeks

DATA TO TRAIN

Typical 6-week per cycle

WET LAB TO VALIDATE

AI TO CREATE

Absci's rapid cycle times aims to:

01

Rapidly iterate and improve AI models

02

Reduce preclinical development timelines and increase clinical PoS

03

Accelerate Industry progress and attract top AI talent

Absci is the first to design and validate new antibodies with zero-shot generative AI

Breakthrough in *de novo* Drug Creation

De novo drug creation with 'zero-shot' generative AI

- Zero-Shot: Model has never seen an antibody that binds to the target or homologs

- Binders were identified straight out of the model – no lead optimization was performed

- Demonstrated across four therapeutic targets: HER2, VEGF-A, COVID omicron, undisclosed target

Unlocking *de novo* antibody design with generative AI

AI Model generated highly diverse and effective binders from massive search space

SIZE OF SEARCH SPACE:

| MILLIONS | BILLIONS | TRILLIONS | QUADRILLIONS |

MEASURED BINDING AFFINITY ($-\log_{10}(K_D)$)

SEQUENCE DIVERSITY (EDIT DISTANCE TO TRASTUZUMAB)

- - - WILDTYPE

AI-Designed & Wet Lab Validated HER2 Binders

- Hundreds of binders created

- Ability to generate binders near to and far from trastuzumab

- Binding affinity maintained even when mutating >90% of the CDR3 region

- All binders to HER2 and HER2 homologs removed from the training dataset

AI model is broadly applicable enabling higher potential therapeutics

Better therapeutics, faster

- Successfully designed antibody variants with higher Naturalness score
- The Naturalness score is associated with developability metrics such as immunogenicity

Model is validated and broadly applicable

- Successfully demonstrated across four therapeutic targets: HER2, VEGF-A, COVID omicron, undisclosed target

Rapid progress towards fully *in silico* drug creation

Unlocking new and differentiated value drivers

Higher Potential Biologics with Increased PoS

Multidimensional optimization in parallel creates higher quality biologics with an increased Probability of Success

Reducing Time & Increasing Competitiveness

Drug creation process is significantly shortened, reducing research costs and increasing competitiveness

Increasing Options for Personalized Medicine

Specific Epitope targeting increases options for personalized medicine

Broadening Intellectual Property Space

AI-driven drug creation generates valuable Intellectual Property

Better Biologics Faster
Accelerating time to clinic while increasing PoS

Patent Life	DISCOVERY & PRECLINICAL					CLINICAL DEVELOPMENT						COMMERCIALIZATION							
	1Y	2Y	3Y	4Y	5Y	6Y	7Y	8Y	9Y	10Y	11Y	12Y	13Y	14Y	15Y	16Y	17Y	18Y	19Y	20Y

Traditional ~4-6 YEARS   ~8 YEARS

POTENTIALLY ACCELERATING TIMELINES

- $10m-15m
- 4-6 years
- Sup-optimal candidate in clinic

vs. Absci ~2 YEARS   < 8 YEARS   LONGER TIME ON PATENT FOR COMMERCIALIZATION

- $5m-7m
- <2 years
- Optimal candidate properties into clinic

- ACCELERATED TIME TO CLINIC
- CANDIDATE WITH OPTIMAL PROPERTY PROFILE INCREASES CLINICAL POS WITH CHANGE FOR SHORTER DEVELOPMENT
- EXPANDED PORTFOLIO WITH MORE 'SHOTS ON GOAL'
- POTENTIALLY LONGER TIME ON PATENT INCREASING BACK-END REVENUES

Technology **validated** through industry-leading partnerships

MERCK

BioSpace
"Merck leans into AI with $610M in biobucks for Absci drug discovery pact"

"At Merck we are continually evaluating new ways to build, expand, and refine our biologics capabilities. Absci's platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins."*

Dr. Fiona Marshall
Former SVP, Head of Discovery, Preclinical and Translational Medicine

EQRx

"EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs"

"Absci's technology platform enables rapid discovery and production of well-differentiated protein-based drugs that are elusive to other discovery approaches. We are excited to work with Absci..."

Dr. Carlos Garcia-Echeverria
Chief of Rx Creation

Well positioned to revolutionize AI drug creation

>200	Unlimiters with deep experience in AI, immunology, synthetic biology, and protein expression
77,000 Square Feet	State-of-the-art drug creation and wet lab space in Vancouver WA, with Absci AI Research (AAIR) lab in NYC, and Innovation Centre in Zug Switzerland
17	Active Programs* with leading partners
>$160M	Strong cash position with >$160M at end of '22**
>200	Patents filed worldwide with dozens more expected in 2023
Billions	High quality high-throughput protein-protein interaction data can be generated a week

* Active Programs: programs in which we have negotiated, or expect to negotiate, license agreements for downstream milestones and royalties. Count as of 9/30/22 10Q filing.
**Unaudited Cash and cash equivalents and short-term investments

absci | 18

The right leadership team to accomplish the Impossible

Executive Leadership

SEAN MCCLAIN
Founder & CEO Director

ANDREAS BUSCH, PHD
Chief Innovation Officer

GREG SCHIFFMAN, CPA
Chief Financial Officer

SARAH KORMAN, PHD, JD
Chief Legal Officer

DENISE DETTORE
Chief People Officer

JACK GOLD
Chief Marketing Officer

PENELOPE
Chief Morale Officer

Board of Directors

IVANA MAGOVCEVIC-LIEBISCH, PhD, JD
CEO & President, Vigil Neuroscience

ZACH JONASSON, PhD
Managing Partner, PVP

KAREN MCGINNIS, CPA
Former CAO, Illumina

AMRIT NAGPAL
Managing Director, Redmile Group

JOSEPH SIROSH, PhD
Vice President, Alexa Shopping, Amazon

DAN RABINOVITSJ
VP Connectivity, Meta

Leadership experience from: BAYER · AMGEN · Shire · hp · illumina · BeiGene · MIT · HARVARD UNIVERSITY · OpenAI · PVP · (vigil) NEURO · Redmile Group · NIKE · amazon · Meta

Absci is leading the way in AI drug creation towards breakthrough therapeutics at the click of a button

Fully *in silico* drug creation

AI de novo Antibody design

AI Lead Optimization

Integrated Drug Creation Platform

Scalable wet-lab technologies

INNOVATION & VALUE CREATION

10 YEARS AGO

2 YEARS AGO

TODAY

This **revolution** is only just beginning.